Aminoglycoside Dosing and Monitoring

Additional Information

Refer to the full document for amikacin dosing

General references and nomograms

  • Drew RH. Dosing and administration of parenteral aminoglycosides (revised June 4, 2015). UpToDate. Accessed July 2016.

  • Avent ML et al. Current use of aminoglycosides: indications, pharmacokinetics and monitoring for toxicity. Intern Med J 2011;41:441-449

  • Stankowicz MS et al. Once-daily aminoglycoside dosing: an update on current literature. Am J Health-Syst Pharm 2015;72:1357-64

  • Nicolau DP et al. Experience with a once-daily aminoglycoside program administered to 2184 adult patients. Antimicrob Agents Chemother 1995;39:650-5 [Hartford Hospital nomogram]

  • Bailey TC et al. A meta-analysis of extended-interval dosing versus multiple daily dosing of aminoglycosides. CID 1997;24:786-95 [Barnes-Jewish Hospital Guidelines]

  • Anaizi N. Once-daily dosing of aminoglycosides: a consensus document. Int J Clin Pharmacol Ther 1997;35:223-6

  • Sarubbi FA et al. Amikacin serum concentrations: prediction of level and dosing guidelines. Ann Int Med 1978;89:612-8

  • Aminoglycosides high dose extended interval dosing/monitoring guidelines. In: Bugs & Drugs, an antimicrobial/infectious diseases reference. p. 59-63, 2012

  • Aminoglycosides conventional dosing/monitoring guidelines. In: Bugs & Drugs, an antimicrobial/infectious diseases reference. p.64-67, 2012

  • Aminoglycoside antibiotics – dosing and monitoring guidelines. In: Capital Health Antimicrobial Handbook. p. 22-27, 2012

Pediatric reference

  • IWK Health Centre Aminoglycosides dosing & monitoring guidelines. April 2014.

Cystic fibrosis references

  • Flume PA et al. Cystic Fibrosis Pulmonary Guidelines. Treatment of Pulmonary Exacerbations. Am J Resp Crit Care Med 2009;180:802-808

  • Prescott WA et al. Extended-interval once-daily dosing of aminoglycosides in adult and pediatric patients with cystic fibrosis. Pharmacotherapy 2010;30(1):95-108

  • Smyth AR, Bhatt J. Once-daily versus multiple-daily dosing with intravenous aminoglycosides for cystic fibrosis. Cochrane Database of Systematic Reviews 2014, Issue 2, Art. No.:CD002009.

  • Smyth A et al. Once versus three-times daily regimens of tobramycin treatment for pulmonary exacerbations of cystic fibrosis – the TOPIC study: a randomized controlled trial. Lancet 2005;365:573-78

  • Stenbit AE et al. Timing of inhaled tobramycin affects assessment of intravenous tobramycin pharmacokinetic monitoring. Journal of Cystic Fibrosis 2013;12:403-406

Dialysis references

  • Dager WE et al. Aminoglycosides in intermittent hemodialysis: pharmacokinetics with individual dosing. Ann Pharmacother 2006;40:9-14

  • Teigen MMG et al. Dosing of gentamicin in patients with end-stage renal disease receiving hemodialysis. J Clin Pharmacol 2006;46:1259-1267

  • Heintz BH et al. Clinical experience with aminoglycosides in dialysis-dependent patients: risk factors for mortality and reassessment of current dosing practices. Ann Pharmacother 2011;45:1338-45

  • Agarwal R and Weir MR. Dry Weight: A Concept Revisited in an Effort to Avoid Medication-Directed Approaches for Blood Pressure Control in Hemodialysis Patients. Clin J Am Soc Nephrol. 2010 Jul;5(7):1255-1260

Peripartum references

  • Ward K et al. Once-daily dosing of gentamicin in obstetrics and gynecology. Clin Obstet Gynecol 2008;51(3):498-506